
    
      The study will consist of a 30-day screening period, a 48-week double-blind treatment period
      and a 30-day safety follow-up period.

      At or after week 24, participants with an inadequate response could receive rescue therapy
      with etanercept plus methotrexate until the end of the treatment period.
    
  